Glen Evans has lived the inventor’s dream. He came up with a brilliant idea, founded a biotech start-up called Egea Biosciences, Inc., and then sold it to Johnson & Johnson in 2004 for millions of dollars.
“One could say that Egea was really built upon [a] patent,” says Evans, 53. Getting that patent, however, was far from easy. When he first met with McDermott Will & Emery counsel David Gay in 2001, Evans had what he calls “a messy case.” “[Evans] needed help and was sophisticated enough to know he needed help,” says Gay, who was introduced to Evans by a venture capitalist who had invested in Egea.
